This document discusses cervical cancer and its prevention through screening and HPV vaccination. It notes that cervical cancer is the most common cancer in Indian females, with 1 in 5 worldwide cases occurring in India. Regular Pap screening can detect precancerous lesions early and HPV vaccination can prevent infection from high-risk HPV types that cause most cervical cancers. The document provides details on HPV, screening guidelines, abnormal Pap results, and cervical cancer prevention recommendations.
The presentation describes various facts about breast and cervical cancer including burden of disease, survival outcomes, need for early diagnosis and screening recommendations.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
The presentation describes various facts about breast and cervical cancer including burden of disease, survival outcomes, need for early diagnosis and screening recommendations.
Say no to cervical cancer-PUBLIC Awareness-Life Care Centre_Dr.Sharda JainLifecare Centre
Cervical Cancer in INDIA
Say no to cervical cancer
Dr.Sharda Jain
Life Care Centre
PUBLIC Awareness_Dr.Sharda Jain
HPV Infection
HPV Vaccination
Cervical Screening
SEE & TREAT Programme tp Prevent Cervical Cancer
Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
HPV Infection , HPV Vaccination , Cervical cancer , Cancer in India , Dr. SHA...Lifecare Centre
HPV inefection , HPV disease prevention, Cervical cancer prevention , Cervical cancer treatment, Female cancer , Female cancer prevention , Uterine cancer , Cancer in india
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
Cervical Cancer is common worldwide , ranking 3rd among all malignancies for women.
Second leading cause of cancer death.
Most of these cancers stem from infection with the Human Pappiloma Virus (HPV).
UPDATE HPV Vaccination IN Cervical Cancer Prevention Dr Sharda Jain Lifecare Centre
Cervical Cancer In India: A Preventable Tragedy That Requires Urgent Attention
It is estimated that in India, about 160 million women aged 30-59 years are at risk of developing cervical cancer, with fatality rate of 50 per cent
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
HPV Infection , HPV Vaccination , Cervical cancer , Cancer in India , Dr. SHA...Lifecare Centre
HPV inefection , HPV disease prevention, Cervical cancer prevention , Cervical cancer treatment, Female cancer , Female cancer prevention , Uterine cancer , Cancer in india
HPV Vaccination, Cerviocal Cancer : Do we need it
for Prevention of cervical cancer &
other HPV related diseasesm,
Presentation Outlines
Cervical cancer disease burden
Prevention with HPV vaccination
Vaccination of sexually active women
Opportunity of Postpartum HPV vaccination
Importance of genital warts prevention
Real world effectiveness data
Safety of HPV vaccine
Cervical Cancer is common worldwide , ranking 3rd among all malignancies for women.
Second leading cause of cancer death.
Most of these cancers stem from infection with the Human Pappiloma Virus (HPV).
UPDATE HPV Vaccination IN Cervical Cancer Prevention Dr Sharda Jain Lifecare Centre
Cervical Cancer In India: A Preventable Tragedy That Requires Urgent Attention
It is estimated that in India, about 160 million women aged 30-59 years are at risk of developing cervical cancer, with fatality rate of 50 per cent
The Cervical Cancer is the second most common cancers and it can be easily prevented by timely screening & proper education, awareness program for women.
Leucorrhoea or whites is a condition in which there is an excessive whitish or colourless secretion from the vagina. Most of the time, it is an exaggeration of the normal (physiological) secretion. Sometimes the cause is the irritation anywhere in the genital organs, due to the common infections of the genital tract (pathological).
50 Ways to Become More Professionally ExcellentLeslie Bradshaw
This presentation will give you practical, next-level tips to help you become the best version of your professional self.
After powering through it, you will be armed with the tactics you need to grow and nurture your network, deliver world class work product, earn trust and respect, successfully collaborate, and generally take your game up a notch so you advance your career (and have plenty of fun along the way).
Insights will come from successful professionals, pop culture, and Bradshaw's own learnings as a sought-after employee, effective leader, and industry-recognized pioneer.
This presentation was originally delivered as a part of the University of Chicago Alumni Career Program on May 19, 2015.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
3. Cervical Cancer
Breast Cancer
Ovarian cancer
Colorectal Cancer
Uterine cancer
4. MOST COMMON CANCER OF FEMALES IN INDIA.
1 in 5 CASES OF CERVICAL CANCER WORLDWIDE IS
FROM INDIA.
SECOND MOST COMMON CANCER WORLDWIDE.
LEADING CAUSE OF DEATH IN FEMALES.
EASIEST CANCER IN FEMALES TO PREVENT THROUGH
SCREENING AND VACCINATION.
5. OVARIAN CANCER IS SECOND MOST
COMMON CANCER SEEN BY THE
GYNAECOLOGISTS IN INDIA.
BREAST CANCER IS THE SECOND COMMONEST
MALIGNANCY OF FEMALES.
6. TESTING ASYMPTOMATIC POPULATION TO
DETECT PRECANCEROUS LESIONS OR EARLY
STAGE OF CANCER.
EFFECTIVE SCREENING AVAILABLE FOR
CERVICAL AND BREAT CANCER.
7.
8. 42 YEARS FEMALE, 2 CHILDREN C/O
IRREGULAR BLEEDING PV - 6 MTHS. WITH
ANEMIA.
70 YEAR FEMALE , 5 CHILDREN C/O
BLEEDING AFTER MENOPAUSE ,FOWL
SMELLING DISCHARGE.
40 YEAR INSPECTOR POLICE, 2 CHILDREN C/O
HEAVY AND PROLONGED BLEEDING SINCE 1
YEAR.
9. BLEEDING FOLLOWING COITUS
IRREGULAR BLEEDING IN BETWEEN PERIOD
HEAVY OR PROLONGED BLEEDING
POSTMENOPAUSAL BLEEDING
VAGINAL DISCHARGE
PAIN
URINARY SYMPTOMS AND RECTAL BLEEDING
WT. LOSS,WEAKNESS
ASYMPTOMATIC
10. ALL CASES OF VAGINAL
DISCHARGE ARE NOT DUE TO
CANCER CERVIX.
CAUSE CAN BE-
physiological
pathological
11. SECRETIONS FROM GLANDS AND VAGINAL
TRANSUDATE.
COLOUR
AMOUNT
LEUKORRHEA
excessive normal vaginal discharge.
◦ Fear of cancer and STD
◦ Cause-puberty, chronic cervicitis, erosion ,polyp
OCP ,regular douching,sedentary occupation
13. HPV INFECTION
EARLY MARRIAGE
MULTIPLE SEX PARTNERS
MUTIPLE BIRTH
CIGARETTE SMOKING
LOW SOCIOECONOMIC STATUS
POOR PERSONAL HYGIENE
14. The main cause of cervical cancer is infection with
Human Papillomavirus or HPV.
Virus that is spread by sex.
Infection is asymptomatic.
There are many different types of HPV-low and high
risk.
Certain “high-risk” HPV types can cause cell changes
and cervical cancer
15. MAJORITY OF FEMALES ACQUIRE HPV BY 30
YEARS.
MOST CLEAR THE INFECTION WITHIN 1-2
YEARS.
ONLY IN FEW –PRECANCEROUS CHANGES
WHICH MAY RESOLVE OR DEVELOP CANCER
OVER 10-20 YEARS.
SEVERAL TYPES OF HPV AROUND 100.
13 TYPES CAUSE CANCER.
16. Most men and women who have had
sex(vaginal,oral,anal) acquire HPV within 2
years of active sexual life.
People who are not sexually active almost never
acqire HPV infection.
Correct and consistent use of condoms can
reduce HPV transmission.Areas not covered
can be infected hence not absolute protection.
17. CAUSATIVE AGENT IN MAJORITY OF CASES
OF CERVIX CANCER.
SEVERAL TYPES- TYPE 16 AND 18
(ASSOCIATED WITH70% CASES OF CANCER
CERVIX).
19. Anyone who has had more than one sex
partner .
Anyone whose sex partner(s) has had
more than one sex partner .
20. Get regular Pap tests and follow up, if
necessary.
Limit your number of sex partners
Choose a sex partner who has had no or few
prior sex partners
Do not smoke cigarettes.
Keep a healthy diet and lifestyle.
Use condoms consistently and correctly
during sexual activity.
21. CERVICAL CANCER PREVENTABLE BY
REGULAR SCREENING.
METHODS OF SCREENING
PAP SMEAR
(CONVENTIONAL,LIQUID BASED
CYTOLOGY)
HIGH RISK HPV TESTING
22. TO BEGIN AT 21 YEARS (EXCEPTIONS- HIV
POSITIVE,IMMUNOCOMPROMISED OR YOUNG PT.
WITH PREVIOUSLY TREATED HIGH GRADE
PRECANCEROUS OR CANCER .
STOP SCREENING AT 65 YRS AGE IN THOSE WITH
PREVIOUSLY NORMAL SCREEN AND NO HIGH RISK
FACTORS.
SCREENING GUIDELINES SAME FOR HPV
VACCINATED .
23. PRESENT VACCINES DO NOT PROTECT
AGAINST ALL HPV TYPES THAT CAN
CAUSE CANCER.
24. SCREEN WITH PAPS 3 YEARLY
HPV COTESTING WITH PAPS- 5 YEARLY
HPV TESTING NOT DONE BEFORE 30 YEARS
25. NO LONGER ANNUAL PAPS .
LATEST RECOMMENDATION 3 YEARLY.
UNNECESSARY COLPOSCOPY DUE TO ANNUAL
SCREEN.NO ADDITIONAL BENEFIT.
NEGLIGIBLE RISK OF MISSING CANCER WITH
3 YRLY SCREEN.
26. BEGIN SCREENING ON DIAGNOSIS (CDC)/21
YEARS(ACS).
SCREEN EVERY 6 MTHS. FOR FIRST YEAR AFTER
DIAGNOSIS.
1 YEARLY PAPS SUBSEQUENTLY.
COLPOSCOPY TOFOLLOW ABNORMAL PAP .
(CENTRE FOR DISEASE CONTROL AND
PREVENTION)
27. BEGIN AT 21 YEARS IRRESPECTIVE OF SEXUAL
INITIATION OR NO. OF SEX PARTNERS.
SCREENING BEFORE THIS AGE-HIV
POSITIVE,IMMUNOCOMPROMISED,PREVIOUSLY
TREATED PRECANCEROUS OR CANCER.
PRECANCEROUS LESIONS MORE LIKELY TO
REGRESS.ALSO HPV INFECTION CLEARS IN
MAJORITY.
DON’T REQUIRE IMMEDIATE COLPOSCOPY AND
TREATMENT.
28. AT 65YEARS PROVIDED 3CONSECUTIVE
NEGATIVE PAPS OR2 CONSECUTIVE NEGATIVE
COTEST(PAPS WITH HPV) WITHIN 10
YEARS.MOST RECENT TEST WITHIN PAST 5
YEARS.
CIN2,CIN3,AIS TO CONTINUE SCREENING FOR
20 YEARS AFTER NORMAL REPORT OR
TREATMENT.
29. Just like mammogram screening, Pap testing is
not a one-time test.
The test is not perfect.
New changes (abnormalities) can occur after you
get tested, even if you have not had new
partners.
It could take many years for changes to develop
or to be noticed.
Your risk changes if you have new partners, or if
your partner has other partners.
30. Cells are collected from the surface of your
cervix by a doctor.
These cells are then checked under a
microscope for any abnormalities.
If abnormal (or precancerous) cells are found,
they can be treated before they turn into
cancer.
Cervical cancer can be found in the early
stages, when it is easier to treat.
31. SENSITIVITY (47-62%)
CAUSE OF LOW SENSITIVITY-
inappropriate site,inadequate
sample,poor quality smear due to delay in
fixing or blood,lab errors in interpretation.
32.
33.
34.
35.
36.
37.
38. HOW IS IT DONE
METHODS-THINPREP TEST AND AUTOCYTE
PREP.
TESTING-HYBRID CAPTURE OR PCR
TECHNIQUE
ADVANTAGE-BETTER DETECTION,HPV
TESTING CAN BE DONE SIMULTANEOUSLY.
39. NOT TO BE DONE DURING PERIODS
AVOID FOR 2 DAYS BEFORE SCREEN
douching
tampons
vaginal tablet or gel
intercourse
no birth control foam or jelly
40. That the cells in your cervix are…
Normal
Abnormal:
◦ Minor cell changes of unknown importance, possibly
unrelated to precancer (ASCUS)
◦ Minor cell changes (LSIL)
◦ Moderate to Severe cell changes (HSIL)
Possibly cancerous
41. Abnormal Pap test results are quite common.
They are usually only slightly abnormal.
80-90% of low grade cervical abnormalities
regress on their own.
If followed up and treated early, you can
prevent the abnormality from turning into
cervical cancer.
42. No! Most people get HPV infection, but very
few get cervical cancer
In most cases, HPV infection goes away on its
own
Sometimes, the HPV infection does not go
away after many years. This type is called
“persistent”. It can lead to cervical cancer
43. If you had treatment for precancer or
cancer of the cervix, you will need a Pap
test.
If the cervix was left in place at the time of
your hysterectomy, you will need Pap tests.
44. TREAT INFECTION AND REPEAT
HIGH RISK HPV TESTING
COLPOSCOPY TO LOCALIZE LESION
Excisional/ ablative procedures
CERVICAL PUNCH/CONE BIOPSY
LEEP/LLETZ
CRYO/CAUTERY
LASER ABLATION
45.
46.
47.
48.
49.
50. LACK OF AWARENESS
FEAR OF EXAMINATION AND PAIN
NONAVAILABILITY OF TEST
INCREASED PATIENT LOAD IN HOSPITALS
MAY REQUIRE REPEAT VISIT
51. VISUAL INSPECTION AFTER APPLICATION OF
3-5% ACETIC ACID (VIA).
VISUAL INSPECTION AFTER APPLICATION OF
LUGOL IODINE (VILI).
52. LIQUID BASED CYTOLOGY
COMBINATION OF PAPS WITH HIGH RISK HPV
SCREENING INTERVAL 3-5 YEARLY
HPV VACCINES
53. HPV RESPONSIBLE FOR CERVICAL,VAGINAL
VULVAR,ANAL,OROPHARYNGEAL
CANCER,PRECANCEROUS LESIONS,GENITAL
WARTS.
ALSO ANAL, PENILE ,OROPHARYNGEAL
CANCER AND GENITAL WARTS IN MALES.
54. FIRST INTRODUCED IN 2006.
HPV 16 AND 18 CAUSE 70% OF CERVICAL
CANCERS.
ALL HPV VACCINES PREVENT HPV 16 AND 18
INFECTION.
GIVE STRONGER AND PROLONGED PROTECTION
THAN NATURAL INFECTION.
TWO FDA APPROVED AVAILABLE IN INDIA-
CERVARIX AND GARDASIL.
55. CERVARIX (BIVALENT-16 AND 18 )
GARDASIL(QUADRIVALENT -16 ,18,6, 11)
TYPE 6 AND 11 CAUSE 90% OF GENITAL
WARTS.
NONAVALENT VACCINE NOT YET AVAILABLE
IN INDIA.
56. 3 INJECTIONS I/M OVER 6 MONTHS.
MOST EFFECTIVE WHEN GIVEN BEFORE PERSON IS
SEXUALLY ACTIVE.
INDIAN ACADEMY OF PAEDIATRICS HAS
INCLUDED IN ITS SCHEDULE-
2 DOSES - (9-14 YRS FEMALE)
3 DOSES - (>15 YRS, IMMUNOCOMPROMISED)
FOR 2 DOSES MINIMUM INTERVAL 6 MTHS.
FOR 3 DOSES - 0, 1 / 2 & 6 MTHS.
59. FDA APPROVED.
NO SERIOUS SIDE EFFECTS
HAS BEEN INCLUDED IN MANY
NATIONAL IMMUNIZATION
PROGRAMME INCLUDING UK,USA
AUSTRALIA AND EUROPEAN
COUNTRIES.
60. REGULAR SCREENING AND
PROPHYLACTIC VACCINATION
CAN PREVENT YOU FROM
DEVELOPING THE MOST
COMMON AND DREADFUL
CANCER .PROTECT YOURSELF.